Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 60

1.

Development and Preclinical Application of an Immunocompetent Transplant Model of Basal Breast Cancer with Lung, Liver and Brain Metastases.

Aprelikova O, Tomlinson CC, Hoenerhoff M, Hixon JA, Durum SK, Qiu TH, He S, Burkett S, Liu ZY, Swanson SM, Green JE.

PLoS One. 2016 May 12;11(5):e0155262. doi: 10.1371/journal.pone.0155262. eCollection 2016.

2.

The epigenetic modifier JMJD6 is amplified in mammary tumors and cooperates with c-Myc to enhance cellular transformation, tumor progression, and metastasis.

Aprelikova O, Chen K, El Touny LH, Brignatz-Guittard C, Han J, Qiu T, Yang HH, Lee MP, Zhu M, Green JE.

Clin Epigenetics. 2016 Apr 14;8:38. doi: 10.1186/s13148-016-0205-6. eCollection 2016.

3.

Expression of GATA3 in MDA-MB-231 triple-negative breast cancer cells induces a growth inhibitory response to TGFß.

Chu IM, Lai WC, Aprelikova O, El Touny LH, Kouros-Mehr H, Green JE.

PLoS One. 2013;8(4):e61125. doi: 10.1371/journal.pone.0061125. Epub 2013 Apr 8.

4.

Impact of ischemia and procurement conditions on gene expression in renal cell carcinoma.

Liu NW, Sanford T, Srinivasan R, Liu JL, Khurana K, Aprelikova O, Valero V, Bechert C, Worrell R, Pinto PA, Yang Y, Merino M, Linehan WM, Bratslavsky G.

Clin Cancer Res. 2013 Jan 1;19(1):42-9. doi: 10.1158/1078-0432.CCR-12-2606. Epub 2012 Nov 7.

5.

Silencing of miR-148a in cancer-associated fibroblasts results in WNT10B-mediated stimulation of tumor cell motility.

Aprelikova O, Palla J, Hibler B, Yu X, Greer YE, Yi M, Stephens R, Maxwell GL, Jazaeri A, Risinger JI, Rubin JS, Niederhuber J.

Oncogene. 2013 Jul 4;32(27):3246-53. doi: 10.1038/onc.2012.351. Epub 2012 Aug 13.

6.

Cross-species genomic and functional analyses identify a combination therapy using a CHK1 inhibitor and a ribonucleotide reductase inhibitor to treat triple-negative breast cancer.

Bennett CN, Tomlinson CC, Michalowski AM, Chu IM, Luger D, Mittereder LR, Aprelikova O, Shou J, Piwinica-Worms H, Caplen NJ, Hollingshead MG, Green JE.

Breast Cancer Res. 2012 Jul 19;14(4):R109. doi: 10.1186/bcr3230.

7.

miRNA signature associated with outcome of gastric cancer patients following chemotherapy.

Kim CH, Kim HK, Rettig RL, Kim J, Lee ET, Aprelikova O, Choi IJ, Munroe DJ, Green JE.

BMC Med Genomics. 2011 Nov 23;4:79. doi: 10.1186/1755-8794-4-79.

8.

MicroRNA regulation in cancer-associated fibroblasts.

Aprelikova O, Green JE.

Cancer Immunol Immunother. 2012 Feb;61(2):231-237. doi: 10.1007/s00262-011-1139-7. Epub 2011 Nov 16. Review.

9.

Differential genetic expression in large versus small clear cell renal cell carcinoma: results from microarray analysis.

Bratslavsky G, Sanford T, Srinivasan R, Aprelikova O, Liu J, Quezado M, Merino M, Linehan WM.

J Cancer. 2011;2:271-9. Epub 2011 May 12.

10.

The role of miR-31 and its target gene SATB2 in cancer-associated fibroblasts.

Aprelikova O, Yu X, Palla J, Wei BR, John S, Yi M, Stephens R, Simpson RM, Risinger JI, Jazaeri A, Niederhuber J.

Cell Cycle. 2010 Nov 1;9(21):4387-98. Epub 2010 Nov 17.

11.

The roads to tumor starvation.

Aprelikova O.

Cell Cycle. 2009 Sep 15;8(18):2868. No abstract available.

PMID:
19736517
12.

Melanoma antigen-11 inhibits the hypoxia-inducible factor prolyl hydroxylase 2 and activates hypoxic response.

Aprelikova O, Pandolfi S, Tackett S, Ferreira M, Salnikow K, Ward Y, Risinger JI, Barrett JC, Niederhuber J.

Cancer Res. 2009 Jan 15;69(2):616-24. doi: 10.1158/0008-5472.CAN-08-0811.

13.

Regulation of hypoxia-inducible genes by ETS1 transcription factor.

Salnikow K, Aprelikova O, Ivanov S, Tackett S, Kaczmarek M, Karaczyn A, Yee H, Kasprzak KS, Niederhuber J.

Carcinogenesis. 2008 Aug;29(8):1493-9. doi: 10.1093/carcin/bgn088. Epub 2008 Apr 1.

14.

BRCA1 may modulate neuronal cell cycle re-entry in Alzheimer disease.

Evans TA, Raina AK, Delacourte A, Aprelikova O, Lee HG, Zhu X, Perry G, Smith MA.

Int J Med Sci. 2007 May 12;4(3):140-5.

15.

Global expression analysis of cancer/testis genes in uterine cancers reveals a high incidence of BORIS expression.

Risinger JI, Chandramouli GV, Maxwell GL, Custer M, Pack S, Loukinov D, Aprelikova O, Litzi T, Schrump DS, Murphy SK, Berchuck A, Lobanenkov V, Barrett JC.

Clin Cancer Res. 2007 Mar 15;13(6):1713-9.

16.

Cancers as wounds that do not heal: differences and similarities between renal regeneration/repair and renal cell carcinoma.

Riss J, Khanna C, Koo S, Chandramouli GV, Yang HH, Hu Y, Kleiner DE, Rosenwald A, Schaefer CF, Ben-Sasson SA, Yang L, Powell J, Kane DW, Star RA, Aprelikova O, Bauer K, Vasselli JR, Maranchie JK, Kohn KW, Buetow KH, Linehan WM, Weinstein JN, Lee MP, Klausner RD, Barrett JC.

Cancer Res. 2006 Jul 15;66(14):7216-24.

17.

Role of ETS transcription factors in the hypoxia-inducible factor-2 target gene selection.

Aprelikova O, Wood M, Tackett S, Chandramouli GV, Barrett JC.

Cancer Res. 2006 Jun 1;66(11):5641-7.

18.

Gene expression profiles associated with response to chemotherapy in epithelial ovarian cancers.

Jazaeri AA, Awtrey CS, Chandramouli GV, Chuang YE, Khan J, Sotiriou C, Aprelikova O, Yee CJ, Zorn KK, Birrer MJ, Barrett JC, Boyd J.

Clin Cancer Res. 2005 Sep 1;11(17):6300-10.

19.

Gene expression profiling of microsatellite unstable and microsatellite stable endometrial cancers indicates distinct pathways of aberrant signaling.

Risinger JI, Maxwell GL, Chandramouli GV, Aprelikova O, Litzi T, Umar A, Berchuck A, Barrett JC.

Cancer Res. 2005 Jun 15;65(12):5031-7.

20.

BRCA1, histone H2AX phosphorylation, and male meiotic sex chromosome inactivation.

Turner JM, Aprelikova O, Xu X, Wang R, Kim S, Chandramouli GV, Barrett JC, Burgoyne PS, Deng CX.

Curr Biol. 2004 Dec 14;14(23):2135-42.

21.

The in vitro and in vivo effects of re-expressing methylated von Hippel-Lindau tumor suppressor gene in clear cell renal carcinoma with 5-aza-2'-deoxycytidine.

Alleman WG, Tabios RL, Chandramouli GV, Aprelikova ON, Torres-Cabala C, Mendoza A, Rogers C, Sopko NA, Linehan WM, Vasselli JR.

Clin Cancer Res. 2004 Oct 15;10(20):7011-21. Erratum in: Clin Cancer Res. 2005 Feb 15;11(4):1684. Rodgers, Craig [corrected to Rogers, Craig].

22.

BRCA1-mediated repression of select X chromosome genes.

Jazaeri AA, Chandramouli GV, Aprelikova O, Nuber UA, Sotiriou C, Liu ET, Ropers HH, Yee CJ, Boyd J, Barrett JC.

J Transl Med. 2004 Sep 21;2(1):32.

23.

Regulation of HIF prolyl hydroxylases by hypoxia-inducible factors.

Aprelikova O, Chandramouli GV, Wood M, Vasselli JR, Riss J, Maranchie JK, Linehan WM, Barrett JC.

J Cell Biochem. 2004 Jun 1;92(3):491-501. Erratum in: J Cell Biochem. 2004 Oct 15;93(3):639.

PMID:
15156561
24.

Universal Reference RNA as a standard for microarray experiments.

Novoradovskaya N, Whitfield ML, Basehore LS, Novoradovsky A, Pesich R, Usary J, Karaca M, Wong WK, Aprelikova O, Fero M, Perou CM, Botstein D, Braman J.

BMC Genomics. 2004 Mar 9;5(1):20.

25.

Properties of switch-like bioregulatory networks studied by simulation of the hypoxia response control system.

Kohn KW, Riss J, Aprelikova O, Weinstein JN, Pommier Y, Barrett JC.

Mol Biol Cell. 2004 Jul;15(7):3042-52. Epub 2004 Apr 23.

26.
27.

Microarray analysis reveals distinct gene expression profiles among different histologic types of endometrial cancer.

Risinger JI, Maxwell GL, Chandramouli GV, Jazaeri A, Aprelikova O, Patterson T, Berchuck A, Barrett JC.

Cancer Res. 2003 Jan 1;63(1):6-11.

28.

BRCA1 is a selective co-activator of 14-3-3 sigma gene transcription in mouse embryonic stem cells.

Aprelikova O, Pace AJ, Fang B, Koller BH, Liu ET.

J Biol Chem. 2001 Jul 13;276(28):25647-50. Epub 2001 May 30.

29.

Construction and characterization of recombinant adenoviruses expressing human BRCA1 or murine Brca1 genes.

Campbell M, Aprelikova ON, van der Meer R, Woltjer RL, Yee CJ, Liu ET, Jensen RA.

Cancer Gene Ther. 2001 Mar;8(3):231-9.

30.

BRCA1-associated growth arrest is RB-dependent.

Aprelikova ON, Fang BS, Meissner EG, Cotter S, Campbell M, Kuthiala A, Bessho M, Jensen RA, Liu ET.

Proc Natl Acad Sci U S A. 1999 Oct 12;96(21):11866-71.

31.

BRCA1 protein level is not affected by peptide growth factors in MCF10A cell line.

Aprelikova O, Kuthiala A, Bessho M, Ethier S, Liu ET.

Oncogene. 1996 Dec 5;13(11):2487-91.

PMID:
8957093
32.

Familial tumor syndrome associated with a germline nonfunctional p16INK4a allele.

Yarbrough WG, Aprelikova O, Pei H, Olshan AF, Liu ET.

J Natl Cancer Inst. 1996 Oct 16;88(20):1489-91. No abstract available.

PMID:
8841025
34.

Signalling properties of FLT4, a proteolytically processed receptor tyrosine kinase related to two VEGF receptors.

Pajusola K, Aprelikova O, Pelicci G, Weich H, Claesson-Welsh L, Alitalo K.

Oncogene. 1994 Dec;9(12):3545-55.

PMID:
7970715
35.

The related FLT4, FLT1, and KDR receptor tyrosine kinases show distinct expression patterns in human fetal endothelial cells.

Kaipainen A, Korhonen J, Pajusola K, Aprelikova O, Persico MG, Terman BI, Alitalo K.

J Exp Med. 1993 Dec 1;178(6):2077-88.

36.
37.

FLT4 receptor tyrosine kinase gene mapping to chromosome band 5q35 in relation to the t(2;5), t(5;6), and t(3;5) translocations.

Armstrong E, Kastury K, Aprelikova O, Bullrich F, Nezelof C, Gogusev J, Wasmuth JJ, Alitalo K, Morris S, Huebner K.

Genes Chromosomes Cancer. 1993 Jul;7(3):144-51.

PMID:
7687867
38.

Two alternative mRNAs coding for the angiogenic factor, placenta growth factor (PlGF), are transcribed from a single gene of chromosome 14.

Maglione D, Guerriero V, Viglietto G, Ferraro MG, Aprelikova O, Alitalo K, Del Vecchio S, Lei KJ, Chou JY, Persico MG.

Oncogene. 1993 Apr;8(4):925-31.

PMID:
7681160
39.

FLT4 receptor tyrosine kinase contains seven immunoglobulin-like loops and is expressed in multiple human tissues and cell lines.

Pajusola K, Aprelikova O, Korhonen J, Kaipainen A, Pertovaara L, Alitalo R, Alitalo K.

Cancer Res. 1992 Oct 15;52(20):5738-43. Erratum in: Cancer Res 1993 Aug 15;53(16):3845.

40.

A radiation hybrid map of 18 growth factor, growth factor receptor, hormone receptor, or neurotransmitter receptor genes on the distal region of the long arm of chromosome 5.

Warrington JA, Bailey SK, Armstrong E, Aprelikova O, Alitalo K, Dolganov GM, Wilcox AS, Sikela JM, Wolfe SF, Lovett M, et al.

Genomics. 1992 Jul;13(3):803-8.

PMID:
1322355
41.

FLT4, a novel class III receptor tyrosine kinase in chromosome 5q33-qter.

Aprelikova O, Pajusola K, Partanen J, Armstrong E, Alitalo R, Bailey SK, McMahon J, Wasmuth J, Huebner K, Alitalo K.

Cancer Res. 1992 Feb 1;52(3):746-8.

42.
43.

[The levels of DNA repair in the cells of diploid and tetraploid cell cultures].

Kudriavtsev BN, Aprelikova ON, Ni VV, Semenova EG, Sukhikh TR.

Tsitologiia. 1991;33(4):77-83. Russian.

PMID:
1666466
44.

[Uracil, contained in DNA, can direct the correction of mispaired nucleotides in human cells].

Golubovskaia VM, Aprelikova ON, Tomilin NV.

Mol Gen Mikrobiol Virusol. 1990 Dec;(12):10-2. Russian.

PMID:
2084540
45.

Changes in the size of pulse-labelled DNA fragments induced in human cells by inhibitors of uracil-DNA glycosylase and DNA methylation.

Aprelikova ON, Golubovskaya VM, Kusmin IA, Tomilin NV.

Mutat Res. 1989 Aug;213(2):135-40.

PMID:
2761553
46.

[UNG-dependent correction of molecular heteroduplexes of M13 phage DNA in Escherichia coli cells].

Golubovskaia VM, Aprelikova ON, Tomilin NV.

Mol Gen Mikrobiol Virusol. 1989 Jul;(7):24-9. Russian.

PMID:
2682222
47.

Uracil-DNA glycosylases and DNA uracil repair.

Tomilin NV, Aprelikova ON.

Int Rev Cytol. 1989;114:125-79. Review. No abstract available.

PMID:
2500405
48.

[Purification and various properties of uracil-DNA-glycosylase from human placenta].

Kuz'min IA, Golubovskaia VM, Aprelikova ON.

Biokhimiia. 1988 Jun;53(6):1002-8. Russian.

PMID:
3179346
49.

[Genetic transformation of somatic cells. XIV. Expression of gene coding for the human hepatitis B virus surface antigen in mammalian cells].

Aprelikova ON, Mikhaĭlov VM, Tomilin NV, Bychko VV, Pumpen PP.

Tsitologiia. 1987 Apr;29(4):484-9. Russian.

PMID:
3603707
50.

[Uracil in DNA].

Aprelikova ON.

Mol Gen Mikrobiol Virusol. 1986 May;(5):3-10. Review. Russian.

PMID:
3540638

Supplemental Content

Loading ...
Support Center